AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04135833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711
Description: BPI-7711 180 mg
Study NCT04135833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg
Study NCT04135833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 600 mg
Study NCT02340598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold vest
Description: The lowering of body temperature increases basal metabolic rate
Study NCT02258321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 tablet
Study NCT02258321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 capsule
Study NCT01109251 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Auto-measure of the tension by an autotensiometer
Description: All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS.
Study NCT01452607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005
Description: 200 mg Ebselen oral capsules (SPI-1005), single dose
Study NCT01452607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg Ebselen oral capsules (SPI-1000), single dose
Study NCT04225299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD®
Description: TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
Study NCT02475551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IdeS
Description: Intravenous infusion
Study NCT01618409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PictureRx card
Description: An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
Study NCT02051946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retroject Device
Study NCT02051946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retroject Device
Study NCT02051946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethacrynic acid injection
Study NCT02051946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balanced salt solution
Study NCT02136576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne
Description: Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
Study NCT02136576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crest Cavity Protection & MI Paste Plus
Description: Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
Study NCT02136576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinpro 5000
Description: Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
Study NCT01982851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural de novo
Description: Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
Study NCT01982851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSE
Description: The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
Study NCT01571414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200-mg tablets once a day
Study NCT01571414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: 600-mg tablets once a day
Study NCT01571414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Description: 400-mg/100-mg tablets twice a day
Study NCT01571414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin (RIF)
Description: 300-mg capsules once a day
Study NCT02273895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: 0.3 mg/mL, intravenously, once
Study NCT01420445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD001 dose level 1
Description: three times daily / 7 days
Study NCT01420445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD001 dose level 2
Description: three times daily / 7 days
Study NCT01420445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pelargonium sidoides extract
Description: 6-9mL three times daily / 7 days
Study NCT01420445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: three times daily / 7 days
Study NCT03297385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
Study NCT03065244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
Study NCT03065244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
Study NCT03849833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: cholecalciferol, Vitamin D3
Description: Vitamin D3 as dietary supplement
Study NCT04448405 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire for evaluation of confinement on deviant sexual fantasies
Description: Questionnaire for evaluation of confinement on deviant sexual fantasies. Population already followed for deviant fantasies
Study NCT01285245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kineret
Description: once daily 100 mg of kineret subcutaneously for 8 days
Study NCT00108160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin Ointment [Treatment]
Description: The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
Study NCT00108160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene Glycol Ointment [Placebo]
Description: The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
Study NCT02922907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: arabinoxylan rice bran
Description: a proprietary product derived from rice bran treated with extracts from three mushrooms
Study NCT02922907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for arabinoxylan rice bran
Description: inactive product
Study NCT03891420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galidesivir
Description: Galidesivir IV infusion
Study NCT03891420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion
Study NCT00680433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
Study NCT00680433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
Study NCT04341142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological tests will be applied on patients blood sampling
Description: Application of tests on patients' serum
Study NCT03184350 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Adjuvant pelvic proton radiation
Description: Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
Study NCT04576611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: face-to-face protocol
Description: The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).
Study NCT04576611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-managed protocol
Description: Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
Study NCT03594279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization
Description: Community Mobilization
Study NCT03594279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization and Community Incentive
Description: Community Mobilization and Community Incentive
Study NCT03556579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A with new UV blocker
Description: Test Lens
Study NCT03556579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Control Lens
Study NCT01951157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Powder for solution for infusion
Study NCT01951157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Powder for solution for infusion
Study NCT01951157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (PM01183)
Description: Powder for concentrate for solution for infusion
Study NCT02368795 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Stent
Description: A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
Study NCT02368795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Indomethacin 100 mg suppository ten minutes before ERCP
Study NCT03472690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBECO-SSI
Description: Subcutaneous injection
Study NCT03472690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT02544373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP therapy
Description: Positive airway pressure treatment for obstructive sleep apnea
Study NCT02544373 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PAP therapy
Description: Positive airway pressure treatment for obstructive sleep apnea
Study NCT03241004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Mask
Description: sleep mask applied for two separate 60-minute periods during anesthesia
Study NCT03597282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01
Description: Personal Cancer Vaccine
Study NCT03597282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD-1
Study NCT02368795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Description: Indomethacin 100 mg suppository ten minutes before ERCP
Study NCT02368795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Sublingual Isosorbide dinitrate 5 mg before ERCP
Study NCT03597282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant
Study NCT02368795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Sublingual Isosorbide dinitrate 5 mg before ERCP
Study NCT02368795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
Study NCT03597282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APX005M
Description: monoclonal agonist antibody against CD40
Study NCT03597282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: monoclonal antibody against CTLA4
Study NCT01927042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECHOs plus TAU
Description: A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
Study NCT01927042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
Study NCT02368795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's lactate
Description: IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
Study NCT00468403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Pancreatic Islet Cells
Description: Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
Study NCT00468403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
Study NCT00468403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
Study NCT00468403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
Study NCT00468403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
Study NCT00468403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of islet cells
Description: The infusion of allogeneic pancreatic islet cells (islet transplant\[s\]) will occur intraportally.
Study NCT05025696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blacksoap(R)
Description: Blacksoap(R)
Study NCT05025696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blacksoap(R)
Description: Blacksoap(R)
Study NCT03254355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Description: 12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
Study NCT02231268 — intervention group
Intervention type: DRUG
Intervention: Gladem
Study NCT00963768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 28431754
Description: A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
Study NCT00963768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
Study NCT04208087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-722
Description: SI-722 will be intravesically instilled.
Study NCT04208087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be intravesically instilled.
Study NCT02450968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02450968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01345383 — intervention group
Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
Study NCT02502981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25mg orally once a day for 40 weeks
Study NCT02502981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlortalidone
Description: 25mg orally once a day for 40 weeks
Study NCT01345552 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery (SRS)
Description: Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
Study NCT03951090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Results of the brief geriatric assessment
Description: Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
Study NCT02070705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI
Study NCT03951090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No results of brief geriatric assessments
Description: Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
Study NCT02201836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One time music therapy
Study NCT02201836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group music therapy
Study NCT02412059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Study NCT02064608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: mTOR inhibitor
Study NCT02774655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pai APP
Description: prescribed 100 PAI weekly
Study NCT02774655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit APP
Description: prescribed 10000 steps daily
Study NCT01058941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoic acid and fish oil concentrate
Description: Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
Study NCT01058941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo LA and placebo oil capsules for 18 months